. The safety of bevacizumab . Expert Opin Drug Saf 2006 ; 5 : 289 – 301 . 13. Jain RK . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy . Nat Med 2001 ; 7 : 987 – 989 . 14
Search Results
Lainie Martin and Russell J. Schilder
Presented by: Mitesh J. Borad
,” commented Dr. Borad. Immunotherapy The combination of antiangiogenics with immune checkpoint inhibitors (atezolizumab + bevacizumab) is a recommended option for certain patients. “We know that hepatocellular cancers have a tumor microenvironment in a
Presented by: Robert I. Haddad
According to Dr. Haddad, other research looking at targets besides immunotherapy has been “disappointing.” A long-running phase III trial of chemotherapy with or without bevacizumab in patients with recurrent/metastatic HNSCC showed no statistically
Denise Leung, Xiaosi Han, Tom Mikkelsen, and L. Burt Nabors
/print certificate. Release date: November 4, 2014; Expiration date: November 4, 2015 Learning Objectives Upon completion of this activity, participants will be able to: Describe the challenges of MRI assessment in patients receiving bevacizumab
Nikolaos A. Trikalinos, Amy Zhou, Maria B. Majella Doyle, Kathryn J. Fowler, Ashley Morton, Neeta Vachharajani, Manik Amin, Jesse W. Keller, William C. Chapman, Elizabeth M. Brunt, and Benjamin R. Tan
erlotinib plus bevacizumab. Response to Gemcitabine-Based Treatments A total of 88% of patients (50/57) who received a gemcitabine-based regimen were evaluable for response ( Table 2 ), including 37 of 41 patients who received gemcitabine
Matthias Holdhoff and Marc C. Chamberlain
trial. 35 The results of AVAglio and RTOG 0825, 2 studies examining the addition of bevacizumab to radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, were recently presented. 39 , 40 Neither study showed an OS advantage with
Wells A. Messersmith
to determine benefit from adjuvant chemotherapy; there is a similar lack of data for ‘high-risk’ stage II disease and benefit from adjuvant chemotherapy.” 3 Finally, adding the biologic bevacizumab or cetuximab did not appear to offer an advantage
Melinda Telli
German GeparSixto study, 1 the inclusion of carboplatin improved the pathologic complete response (pCR) rate compared with paclitaxel, nonpegylated liposomal doxorubicin, and bevacizumab used alone among those patients with triple-negative breast cancer
Bruce D. Minsky, Claus Rödel, and Vincenzo Valentini
benefit of adding targeted biologic agents, such as bevacizumab and cetuximab, is being tested. Initial phase I/II trials of bevacizumab plus preoperative 5-FU or capecitabine-based chemoradiation revealed pCR rates of 18% to 24%. 17 , 18 However, more
Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, and Jue Wang
, interferon alfa, or both for advanced renal-cell carcinoma . N Engl J Med 2007 ; 356 : 2271 – 2281 . 40 Yang JC Haworth L Sherry RM . A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal